Platelets are the major source of plasma-soluble CD40L (sCD40L), an important inflammatory mediator. This study explored the impact of platelet-derived sCD40L on Behçet disease (BD), an autoinflammatory vasculitis. We also searched for influences by platelet matrix metalloproteinases (MMP) –2 and MMP-9, implicated in several inflammatory diseases, on CD40L shedding from platelet membrane. Platelet activation were studied by flow cytometry and aggregometry, surface expression of CD40L and platelet-leukocyte aggregates by flow cytometry, sCD40L by ELISA, cellular CD40L and CD40 levels by Western blot and MMPs activity by gelatin zymography. The effect of sCD40L on MMP9 expression was studied in cultured MEG-01 cells. Plasma and platelet-released sCD40L levels were higher in BD patients. No differences in platelet activation and in platelet-leukocyte aggregates formation were observed between BD patients and controls. Plasma and platelet MMP-9 levels were increased in BD patients, whereas there was no difference in platelet MMP-2 activity. Since a correlation between plasma sCD40L and platelet MMP-9 activity was observed, we studied the influence of sCD40L on MMP-9 levels in the megakaryoblastic cell line MEG-01. Treatment of MEG-01 cells with recombinant sCD40L increased MMP-9 but did not change MMP-2 levels. In conclusion, sCD40L release from platelets was mediated by MMP-9, and MMP-9 expression was in turn upregulated by sCD40L in the MEG-01 cell line. We conclude that platelets and megakaryocytes might participate in a positive feedback loop occurring between sCD40L and MMP-9 which would contribute to the proinflammatory state observed in BD.
2
Mege JL,
Dilsen N,
Sanguedolce V.
et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549.
7
Menchén L,
Marín-Jiménez I,
Arias-Salgado EG.
et al. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009; 58: 920-928.
8
Choi WS,
Jeon OH,
Kim DS.
CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3). J Thromb Haemost 2010; 08: 1364-1371.
9
Lievens D,
Eijgelaar WJ,
Biessen EA.
et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
10
Lievens D,
Zernecke A,
Seijkens T.
et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
11
Missiou A,
Wolf D,
Platzer I.
et al. CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103: 788-796.
12
Poggi M,
Engel D,
Christ A.
et al. CD40L Deficiency Ameliorates Adipose Tissue Inflammation and Metabolic Manifestations of Obesity in Mice. Arterioscler Thromb Vasc Biol 2011; 31: 2251-2260.
13
Andre P,
Nannizzi-Alaimo L,
Prasad SK.
et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-899.
14
Aukrust P,
Müller F,
Ueland T.
et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
18
Danese S,
de la Motte C,
Fiocchi C.
Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938-945.
20
Bhakta BB,
Brennan P,
James TE.
et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-733.
21
Ogura M,
Morishima Y,
Ohno R.
et al. Establishment of a novel human mega-karyoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
23
Furman MI,
Krueger LA,
Linden MD.
et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-2325.
26
Pay S,
Abbasov T,
Erdem H.
et al. Serum MMP-2 and MMP-9 in patients with Behçet’s disease: do their higher levels correlate to vasculo-Behçet’s disease associated with aneurysm formation?. clin exp rheumatol 2007; 25: s70-75.
27
Descamps FJ,
Kangave D,
Cauwe B.
et al. Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. J Cell Mol Med 2008; 12: 2449-2456.
28
Mason PJ,
Chakrabarti S,
Albers AA.
et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005; 96: 1365-1369.
29
Viallard JF,
Solanilla A,
Gauthier B.
et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99: 2612-2614.
30
Jung K,
Mannello F,
Lein M.
Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. J Transl Med 2009; 07: 87.
31
Gerlach RF,
Demacq C,
Jung K.
et al. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007; 40: 119-123.
32
Ricart JM,
Ramón LA,
Vayá A.
et al. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol 2008; 141: 716-719.
34
Akar S,
Ozcan MA,
Ates H.
et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease. Clin Appl Thromb Hemost 2006; 12: 451-457.
35
Martínez M,
Ricart JM,
Ruiz-Aja S.
et al Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events?. Pathophysiol Haemost Thromb 2007; 36: 18-22.
36
Varo N,
Libby P,
Nuzzo R.
et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005; 02: 81-87.
37
Tousoulis D,
Zisimos K,
Antoniades C.
et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distension. Int J Cardiol 2009; 136: 258-262.
38
Ohashi Y,
Kawashima S,
Mori T.
Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 2006; 112: 52-58.
39
Henn V,
Steinbach S,
Buchner K.
et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
41
Freysdottir J,
Lau S,
Fortune F.
Gammadelta T cells in Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118: 451-457.
42
Hamzaoui K,
Hamzaoui A,
Guemira F.
et al. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-210.
44
Boumpas DT,
Furie R,
Manzi S.
et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
45
Schönbeck U,
Mach F,
Sukhova GK.
et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ Res 1997; 81: 448-454.
47
Smola-Hess S,
Schnitzler R,
Hadaschik D.
et al. CD40L induces matrix-metalloproteinase-9 but not tissue inhibitor of metalloproteinases-1 in cervical carcinoma cells: imbalance between NF-kappaB and STAT3 activation. Exp Cell Res 2001; 267: 205-215.
48
Lollini PL,
Landuzzi L,
Frabetti F.
et al. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 1998; 04: 1843-1849.
49
Mach F,
Schönbeck U,
Fabunmi RP.
et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154: 229-238.
51
Hermann A,
Rauch BH,
Braun M.
et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
52
Cecchetti L,
Tolley ND,
Michetti N.
et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
55
Kato Y,
Tsuda T,
Hosaka Y.
et al. Effects of trapidil on effector functions of monocytes related to atherosclerotic plaque. Eur J Pharmacol 2001; 428: 371-379.
56
Lutgens E,
Lievens D,
Beckers L.
et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
